# Teclistamab in Combination With Daratumumab for High-Risk Smoldering Myeloma: A Clinical and Correlative Phase 2 Immuno-Oncology Study (the REVIVE Study)

> **NCT06100237** · PHASE2 · RECRUITING · sponsor: **Carl Ola Landgren, MD, PhD** · enrollment: 50 (estimated)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Teclistamab
- **DRUG:** Talquetamab
- **DRUG:** Daratumumab SC

## Key facts

- **NCT ID:** NCT06100237
- **Lead sponsor:** Carl Ola Landgren, MD, PhD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-12-04
- **Primary completion:** 2028-12-31
- **Final completion:** 2029-12-31
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2026-02-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06100237

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06100237, "Teclistamab in Combination With Daratumumab for High-Risk Smoldering Myeloma: A Clinical and Correlative Phase 2 Immuno-Oncology Study (the REVIVE Study)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06100237. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*